Spyre Therapeutics | 8-K/A: Current report (Amendment)
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 8-K: Current report
S-1: General form for registration of securities under the Securities Act of 1933
Spyre Therapeutics | DEF 14A: Definitive information statements
Spyre Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Spyre Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Spyre Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Spyre Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Spyre Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Spyre Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Spyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Spyre Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Spyre Therapeutics | 8-K: Current report
No Data